Epidermal growth factor receptor and angiogenesis: Opportunities for combined anticancer strategies

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Tumor growth and metastasis depend on angiogenesis, the formation of new blood vessels.
• Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor (EGF) signaling pathways are critical regulators of tumor angiogenesis.
• Acquired resistance to single-target inhibitors, such as Epidermal Growth Factor Receptor (EGFR) inhibitors, presents a significant clinical challenge.

Purpose of the Study:

• To review the roles of VEGF and EGF signaling in tumor-induced angiogenesis.
• To explore the rationale for combining VEGF and EGF pathway inhibitors in anticancer therapy.
• To discuss the potential of this combination strategy to overcome acquired resistance and improve antitumor activity.

Main Methods:

• Literature review of studies on VEGF, EGF, and their receptors in angiogenesis.
• Analysis of preclinical and clinical data on combined anti-VEGF/anti-EGF therapies.
• Examination of mechanisms underlying acquired resistance to EGFR inhibitors.

Main Results:

• VEGF and EGF signaling pathways are key drivers of tumor angiogenesis.
• Combined inhibition of VEGF and EGF pathways can lead to enhanced antiangiogenic effects.
• Targeting both pathways may circumvent acquired resistance to EGFR inhibitors.
• Preliminary clinical trial data suggest potential for greater antitumor activity with combined inhibition.

Conclusions:

• Combined inhibition of VEGF and EGF signaling pathways represents a promising anticancer strategy.
• This approach holds potential for overcoming resistance and improving therapeutic outcomes in cancer patients.
• Further clinical investigation of combined anti-VEGF and anti-EGF therapies is warranted.